Developing breakthrough treatments for diseases of the ear

Welcome to Synphora

Synphora is a clinical-stage biopharmaceutical company focusing on the development of pharmacological treatments for diseases of the ear, in particular

The current strategy is to build on the therapeutic principle of administering a prostaglandin F2α receptor agonist to the eye. This treatment has been successfully established and has been in worldwide clinical use for the treatment of glaucoma for the last 25 years.

Menière’s disease is typically associated with a retention of fluid in the membranous labyrinth of the inner ear. This is in analogy with glaucoma, where a build up of intra-ocular fluid causes an elevation of intra-ocular pressure and as a consequence damage to the optic nerve. This is why Menière’s disease is often referred to as “glaucoma of the ear”.

There is a large body of experimental work suggesting that prostaglandin F2α receptor agonists are associated with a neuroprotective effect which is distinctly different and additional to their ability to lower the intra-ocular pressure by enhancing the drainage of fluid from the eye. This effect may work equally well for the treatment of noise-induced tinnitus.